Eli Lilly and (NYSE:LLY) has been given a $93.00 price objective by investment analysts at Jefferies Group in a research note issued on Monday. The brokerage presently has a “buy” rating on the stock. Jefferies Group’s price objective points to a potential upside of 17.66% from the company’s current price.
Other equities research analysts also recently issued research reports about the stock. BMO Capital Markets set a $73.00 price objective on shares of Eli Lilly and and gave the company a “sell” rating in a research report on Tuesday, December 5th. Credit Suisse Group reaffirmed a “hold” rating and set a $80.00 price objective on shares of Eli Lilly and in a research report on Friday, February 2nd. JPMorgan Chase & Co. set a $105.00 price objective on shares of Eli Lilly and and gave the company a “buy” rating in a research report on Monday. Argus raised shares of Eli Lilly and from a “hold” rating to a “buy” rating and boosted their target price for the company from $85.52 to $115.00 in a research note on Friday, January 5th. Finally, Bank of America reduced their target price on shares of Eli Lilly and from $88.00 to $86.00 and set a “neutral” rating for the company in a research note on Thursday, February 1st. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and ten have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $93.47.
Shares of Eli Lilly and (NYSE LLY) traded down $1.14 during trading hours on Monday, hitting $79.04. 3,215,081 shares of the company were exchanged, compared to its average volume of 5,235,414. The company has a current ratio of 1.32, a quick ratio of 1.01 and a debt-to-equity ratio of 0.85. Eli Lilly and has a twelve month low of $73.69 and a twelve month high of $89.09. The company has a market cap of $88,290.00, a P/E ratio of 48.78, a PEG ratio of 1.47 and a beta of 0.23.
In other news, major shareholder Lilly Endowment Inc sold 200,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 13th. The shares were sold at an average price of $88.20, for a total value of $17,640,000.00. Following the completion of the sale, the insider now directly owns 123,084,104 shares of the company’s stock, valued at approximately $10,856,017,972.80. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Donald A. Zakrowski sold 900 shares of the company’s stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $81.09, for a total transaction of $72,981.00. Following the completion of the sale, the insider now directly owns 4,130 shares of the company’s stock, valued at $334,901.70. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 260,486 shares of company stock valued at $22,795,340. Company insiders own 0.20% of the company’s stock.
Several large investors have recently modified their holdings of LLY. Avestar Capital LLC acquired a new stake in Eli Lilly and during the fourth quarter valued at approximately $100,000. Gradient Investments LLC acquired a new stake in Eli Lilly and during the fourth quarter valued at approximately $103,000. Acrospire Investment Management LLC lifted its stake in Eli Lilly and by 16.7% during the second quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock valued at $115,000 after purchasing an additional 200 shares during the last quarter. MPS Loria Financial Planners LLC acquired a new stake in Eli Lilly and during the second quarter valued at approximately $128,000. Finally, San Francisco Sentry Investment Group CA acquired a new stake in Eli Lilly and during the second quarter valued at approximately $129,000. 75.71% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This article was first reported by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another publication, it was illegally copied and republished in violation of international copyright and trademark law. The original version of this article can be accessed at https://www.tickerreport.com/banking-finance/3226120/jefferies-group-reiterates-93-00-price-target-for-eli-lilly-and-lly.html.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.